Results 61 to 70 of about 75,353,973 (171)

Intravitreal faricimab in patients with nAMD: French data from the Fight Retinal Blindness! Registry

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess real‐world outcomes of intravitreal faricimab in French patients with neovascular age‐related macular degeneration (nAMD) previously treated with vascular endothelial growth factor (VEGF) inhibitors using data from the Fight Retinal Blindness! (FRB!) Registry.
Eloi Debourdeau, Déborah Harboun, Pierre‐Henry Gabrielle, Yohei Hashimoto, Chloe Chamard, Frederic Michon, Benjamin Wolff, Héloïse Torres‐Villaros, Audrey Giocanti‐Auregan, Mark Gillies, Catherine Creuzot–Garcher, Vincent Daien   +11 more
wiley   +1 more source

Five‐Year Treatment Outcomes of Macular Oedema Secondary to Central Retinal Vein Occlusion in Routine Clinical Practice: The Fight Retinal Blindness! Registry

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To report 5‐year outcomes in a cohort of patients who received anti‐VEGF therapy for macular oedema secondary to central retinal vein occlusion (CRVO) in routine clinical practice. Methods In this retrospective observational study, 593 treatment‐naïve eyes that commenced anti‐VEGF treatment between 1 January 2010, and 2019 were ...
Katrin Rudolph, Marianna Rosso, Mark Gillies, Adrian Hunt, Louise O'Toole, Alessandro Invernizzi, David Squirrell, Hemal Mehta, Richard Barry, Pierre‐Henry Gabrielle, Daniel Barthelmes   +10 more
wiley   +1 more source

Multimodal Exploratory Analysis of Persistent Diabetic Macular Edema: Integrating Aqueous Humour Metabolomics, Clinical and OCT Features

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Purpose This exploratory study integrates aqueous humour metabolomic data with clinical and imaging features to examine candidate biomarkers and characterize multimodal patterns associated with persistent diabetic macular edema (pDME). Methods In this prospective cohort study, DME patients were treated with monthly anti‐VEGF injections over 3 ...
Yunhan Tao, Huimin Yu, Yunxi Ma, Mingzhu Yuan, Guochong Chen, Jun Liu, Xi Chen, Xufang Sun   +7 more
wiley   +1 more source

HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION [PDF]

, 2018
PURPOSE: To determine the efficacy of monthly (0.1 mL/4 mg) aflibercept for refractory neovascular age-related macular degeneration (wet age-related macular degeneration).
Qi Sheng You, Ramkumar, Hema L, William R. Freeman, You, Qi Sheng, Gaber, Raouf, Meshi, Amit, Amit Meshi, Alam, Mostafa, Muftuoglu, Ilkay Kilic, Mostafa Alam, Raouf Gaber, Ilkay Kilic Muftuoglu, Hema L. Ramkumar, Freeman, William R   +13 more
core   +1 more source

Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration

Therapeutic Advances in Ophthalmology
What is this summary about? • This is a summary of a publication about the PULSAR study, which was published in The Lancet scientific journal. • Wet age-related macular degeneration (or AMD) is a long-term eye disease in which abnormal blood vessels grow
Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S. Heier, Sergio Leal, Frank G. Holz, William Lloyd Clark, David Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J. Berliner, Andrea Schulze, Thomas Schmelter, Ursula Schmidt-Ott, Xin Zhang, Robert Vitti, Karen W. Chu, Kimberly Reed, Rohini Rao, Rafia Bhore, Yenchieh Cheng, Tien Y. Wong   +20 more
doaj   +1 more source

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9809-9818, November 2026.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Ziv-aflibercept in macular disease [PDF]

, 2015
Background/aims Aflibercept is an approved therapy for neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved ...
Mansour, Ahmad Mohammed Farid Mahmoud, I Al-Ghadban, Sara, Younis, Muhammad H., El-Sabban, Marwan E.   +3 more
core   +1 more source

Comparison of Efficacy of Suprachoroidal Triamcinolone Acetonide Alone or in Combination With Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema: A Prospective Comparative Study

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims This study was designed to evaluate the safety, efficacy, and durability of suprachoroidal triamcinolone acetonide, administered either alone or in combination with intravitreal bevacizumab (IVB), in the treatment of diabetic macular edema (DME). Methods This prospective comparative interventional study was conducted in the
Muhammad Tahir Ghaffar, Asad Aslam Khan, Mohammad Hasan Bokhari, Tahseen Mahmood Majhu, Faisal Anwar, Chaudhry Nasir Ahmed, Aalaa Saleh   +6 more
wiley   +1 more source

Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration

Ophthalmology
Purpose To report the efficacy, durability, and safety of intravitreal aflibercept 8 mg versus intravitreal aflibercept 2 mg every 8 weeks (2q8) in patients with neovascular age-related macular degeneration (nAMD) through 96 weeks, PULSAR ( ClinicalTrials.gov identifier, NCT04423718).
Korobelnik J. -F., Lanzetta P., Leal S., Holz F. G., Clark W. L., Eichenbaum D., Iida T., Sun X., Berliner A. J., Schulze A., Zhao M., Schmelter T., Schmidt-Ott U., Zhang X., Morgan-Warren P., Hasanbasic Z., Vitti R., Chu K. W., Reed K., Bhore R., Cheng Y., Bai Z., Hirshberg B., Yancopoulos G. D., Wong T. Y.   +24 more
openaire   +1 more source

Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial

International Journal of Cancer, Volume 159, Issue 7, Page 1817-1828, 1 October 2026.
Antiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O. Goetze, Salah E. Al‐Batran, Sonja Loges, Melanie Janning   +17 more
wiley   +1 more source